Xconomy | Boston - Business + Technology in the Exponential Economy

medical devices, FDA, Life Sciences

Boston Scientific Stent, With New Drug Coating, Wins FDA Approval

Luke Timmerman 7/2/08

Boston Scientific (NYSE: BSX) said today the FDA has approved a new type of stent for propping open clogged coronary arteries. The FDA cleared for sale the Promus stent that secretes everolimus, a drug designed to reduce scar tissue around the device and reduce blockages. Natick, MA-based Boston Scientific currently sells the Taxus stent coated with paclitaxel, so the approval means it can now offer stents in the U.S. with two different drugs. The Promus stent is manufactured by Abbott Laboratories, and distributed by Boston Scientific.


Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2008 Xconomy. All rights reserved. Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.